Dr Akbar Khan on Cancer, LDN Radio Show (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Linda Elsegood: Today we're joined by Dr Akbar Khan, who works with LDN and cancer in his Medicor Cancer Centres. He has treated over 2000 patients with LDN, so we are very interested in hearing what he has to say.

Cheryl - US: Lyme Disease (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Cheryl from the United States takes LDN for Lyme disease and Co infections.

Her story  goes back into childhood. She had always struggled with some sort of illnesses. Gastrointestinal issues,  stomach virus, rashes on her face, etc

A Comparison of Medication-Assisted Treatment Options for Opioid Addiction: A Review of the Literature

J Addict Nurs
30 June 2021
https://pubmed.ncbi.nlm.nih.gov/34224485/

Masoud Rashidi, PharmD discusses LDN and Pain (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and β-Endorphin

eNeuro
126 June 2021
https://pubmed.ncbi.nlm.nih.gov/34031099/

Integrated Review of the Assessment of Newborns With Neonatal Abstinence Syndrome

J Obstet Gynecol Neonatal Nurs
08 June 2021
https://pubmed.ncbi.nlm.nih.gov/34116058/

Objective: To critically review and summarize current knowledge regarding the assessment of newborns with neonatal abstinence syndrome (NAS).

Extended-release naltrexone for youth with opioid use disorder

J Subst Abuse Treat
15 April 2021
https://pubmed.ncbi.nlm.nih.gov/34118699/

Background: Few published research studies have examined the effectiveness of extended-release naltrexone (XR-NTX) for the treatment of opioid use disorder (OUD) among adolescents and young adults.

Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review

Pain Physician
July 2021
https://pubmed.ncbi.nlm.nih.gov/34213865/

Background: Complex regional pain syndrome is a rare, neuropathic disorder that affects fewer than 200,000 individuals in the United States annually. Current treatments often focus on pain management and fall short of relieving symptoms of pain and dystonia in patients.

Naltrexone is neuroprotective against traumatic brain injury in mu opioid receptor knockout mice

CNS Neurosci Ther
21 May 2021
https://pubmed.ncbi.nlm.nih.gov/34018697/

Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy

Int Immunopharmacol
11 May 2021
https://pubmed.ncbi.nlm.nih.gov/33989971/